Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
NCT01177800Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2009
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Infliximab with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) at 10 weeks. Started Feb 2009; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01177800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177800.